Скачать с ютуб Hims & Hers Stock Drops 11%: Here's What You Need to Know в хорошем качестве

Hims & Hers Stock Drops 11%: Here's What You Need to Know

Hims & Hers stock fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk asked the FDA to not allow companies to compound GLP-1 semaglutide. This could be a direct hit to Hims & Hers business, but the impact may not be what you think, as Travis Hoium covers in this video.  --------------------------------------------------------------------------------- 💰 If you like this video, check out my free Asymmetric Investing Newsletter for more investment analysis: https://asymmetric-investing.beehiiv.... TRAVIS ON TWITTER:   / travishoium   📊 The charts I use are made with FinChat, the best tool for investment research. I pay for the Pro plan, but you can get started making beautiful charts and asking the AI questions here: https://finchat.io?lmref=OzAxng 📊 20% Off Investment Research Tool Koyfin: https://www.koyfin.com/affiliate/asym... 🎙️ 20% Off Conference Call App Quartr: https://quartr.com/pricing?via=asymme... 🧐Looking for great investment ideas? Visit https://www.fool.com/asym for ten top stock picks from The Motley Fool. A portion of this video is sponsored by The Motley Fool. Visit https://fool.com/asym to get access to my special offer. The Motley Fool Stock Advisor returns are 780% as of 9/26/2024 and measured against the S&P 500 returns of 168% as of 9/26/2024. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well. 00:00 Market Reaction to FDA Lobbying 00:28 Contextualizing the News 00:53 Impact on HIMS and Hers Business 03:58 HIMS and Hers Business Overview 05:24 Disrupting Traditional Healthcare 06:56 Future Prospects and Investor Insights